
ASLAN Pharmaceuticals Limited ASLN
Annual report 2020
added 08-19-2023
ASLAN Pharmaceuticals Limited Gross Profit 2011-2026 | ASLN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit ASLAN Pharmaceuticals Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 2.59 M | - | - | 11.4 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.4 M | 2.59 M | 6.98 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ACADIA Pharmaceuticals
ACAD
|
473 M | $ 22.57 | 0.04 % | $ 3.74 B | ||
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
Akebia Therapeutics
AKBA
|
190 M | $ 1.41 | -1.4 % | $ 363 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
5.51 M | - | 2.54 % | $ 160 B | ||
|
Aravive
ARAV
|
5.68 K | - | -13.39 % | $ 1.45 M | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Aytu BioScience
AYTU
|
45.8 M | $ 2.56 | -3.76 % | $ 16.1 M | ||
|
AstraZeneca PLC
AZN
|
48.1 B | - | - | $ 96.9 B | ||
|
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.85 | -1.39 % | $ 9.26 B | ||
|
Advaxis
ADXS
|
90 K | - | -9.65 % | $ 45.9 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
356 M | $ 20.87 | 2.3 % | $ 976 M | ||
|
Aquestive Therapeutics
AQST
|
32.9 M | $ 4.17 | -0.24 % | $ 446 M | ||
|
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
BeiGene, Ltd.
BGNE
|
4.67 B | - | 0.49 % | $ 251 B | ||
|
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | ||
|
Cabaletta Bio
CABA
|
0.006 | $ 3.17 | 2.59 % | $ 319 M | ||
|
Codiak BioSciences
CDAK
|
2.92 K | - | -55.98 % | $ 2.15 M | ||
|
Avid Bioservices
CDMO
|
7.32 M | - | - | $ 789 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 2.93 | -4.87 % | $ 6.38 B | ||
|
Checkpoint Therapeutics
CKPT
|
1.07 | - | - | $ 169 M | ||
|
CureVac N.V.
CVAC
|
-10.6 M | - | - | $ 867 M | ||
|
Celldex Therapeutics
CLDX
|
5.48 M | $ 33.62 | 3.73 % | $ 2.23 B | ||
|
Concert Pharmaceuticals
CNCE
|
7.9 K | - | - | $ 401 M | ||
|
Celsion Corporation
CLSN
|
500 K | - | -6.63 % | $ 13.9 M |